Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging anticoagulant drugs.

Shannon M Bates1, Jeffrey I Weitz

  • 1Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Arteriosclerosis, Thrombosis, and Vascular Biology
|July 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Dosing Frequency and Dose Influence Thromboxane Suppression Despite Uniform Inhibition of Arachidonic Acid-induced Platelet Aggregation.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Poly(sulfobetaine-<i>co</i>-oligoethylene Glycol Methyl Ether Methacrylate) Copolymers with Improved Anti-Fouling and Anti-Coagulant Properties.

Biomacromolecules·2026
Same author

A novel biosensor for measuring plasmin activity.

Research and practice in thrombosis and haemostasis·2026
Same author

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71.

Blood·2026
Same author

Long-Term Hydrophilic, Anti-Clotting, and Anti-Fibrotic Dynamic Covalent Silicone-Based Biomaterials.

Advanced healthcare materials·2026
Same author

Pharmacologic Factor XI/XIa Inhibitors: What the Laboratory Hematologist Needs to Know.

Clinics in laboratory medicine·2026

New anticoagulant drugs are being developed to overcome the limitations of traditional treatments like heparin and warfarin for preventing and treating blood clots. This study reviews emerging anticoagulant agents in advanced clinical trials.

Area of Science:

  • Pharmacology
  • Hematology
  • Cardiovascular Medicine

Background:

  • Traditional anticoagulants, heparin and warfarin, possess significant limitations.
  • These limitations necessitate the development of novel anticoagulant therapies.
  • Thromboembolism, encompassing both venous and arterial types, remains a critical clinical challenge.

Purpose of the Study:

  • To review the mechanisms of thrombogenesis and its regulation.
  • To focus on novel anticoagulant agents currently in advanced clinical testing.
  • To provide an overview of the next generation of anticoagulant drugs.

Main Methods:

  • Literature review of thrombogenesis and regulation.
  • Focused review of anticoagulant agents in late-stage clinical trials.

Related Experiment Videos

  • Analysis of emerging data on new anticoagulant drug candidates.

    • Main Results:

    • Traditional anticoagulants have inherent limitations impacting patient care.
    • Several new anticoagulant agents are progressing through clinical development.
    • These novel agents aim to improve safety and efficacy profiles.

    Conclusions:

    • The development of new anticoagulants is crucial for managing thromboembolism.
    • Emerging agents show promise in addressing the shortcomings of current therapies.
    • Further research and clinical validation are essential for these novel drugs.